Brian D Gonzalez1, Sarah L Eisel2, Kristina E Bowles3, Aasha I Hoogland1, Brian W James4, Brent J Small5, Susan Sharpe6, Kelly A Hyland7, Hailey W Bulls8, Shannon M Christy9, Jori Mansfield4, Ashley M Nelson10, Raviteja Alla11, Kelly Maharaj12, Brittany Kennedy13, Elizabeth Lafranchise14, Noelle L Williams15, Sarah Jennewein16, Laura B Oswald17, Michael A Postow18, Adam P Dicker19, Heather S L Jim20. 1. Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA. 2. Department of Health Outcomes and Behavior, Moffitt Cancer Center , Tampa, FL, USA. 3. Department of Health Outcomes and Behavior , Moffitt Cancer Center, Tampa, FL, USA. 4. Morsani College of Medicine, University of South Florida, Tampa, FL, USA. 5. School of Aging Studies, University of South Florida, Tampa, FL, USA. 6. Moffitt Biomedical Library, Moffitt Cancer Center, Tampa, FL, USA. 7. Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA. 8. Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA. 9. Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA. 10. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. 11. Morsani College of Medicine, University of South Florida, Tampa, FL, USA. 12. Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA . 13. Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA. 14. Morsani College of Medicine, University of South Florida, Tampa, FL, USA. 15. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 16. Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL , USA. 17. Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa , FL, USA. 18. Southeast Radiation Oncology Group, Levine Cancer Institute at Atrium Health, Charlotte, NC, USA. 19. Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA. 20. Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.
Abstract
BACKGROUND: Trials of immune checkpoint inhibitors (ICIs) have published patient-reported quality of life (QOL), but the size and heterogeneity of this literature can make patient education difficult. This meta-analysis aimed to describe change in QOL and symptomatology in patients receiving ICIs for cancer. METHODS: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, databases were searched through November 2019 for articles or abstracts of prospective, original studies reporting longitudinal QOL in adult cancer patients treated with ICIs. The prespecified primary outcomes were change in global QOL among patients treated with ICIs and difference in change since baseline in global QOL between patients treated with ICI vs non-ICI active treatment. Secondary outcomes included physical functioning and symptomatology. All statistical tests were 2-sided. RESULTS: Of 20 323 publications, 26 met inclusion criteria. Global QOL did not change over time in patients treated with ICIs (k = 26, n = 6974; P = .19). Larger improvements in global QOL was observed in patients receiving ICI vs non-ICI regimens (k = 16, ICI: n = 3588; non-ICI: n = 2948; P < .001). Physical functioning did not change in patients treated with ICIs (k = 14, n = 3169; P = .47); there were no differences in mean change between ICI vs non-ICI regimens (k = 11, n = 4630; P = .94). Regarding symptoms, appetite loss, insomnia, and pain severity decreased, but dyspnea severity increased in patients treated with ICIs (k = 14, n = 3243-3499; P < .001). Insomnia severity was higher in patients treated with ICIs than non-ICI regimens (k = 11, n = 4791; P < .001). CONCLUSIONS: This study is among the first to quantitatively summarize QOL in patients treated with ICIs. Findings suggest ICI recipients report no change in global QOL and higher QOL than patients treated with non-ICI regimens.
BACKGROUND: Trials of immune checkpoint inhibitors (ICIs) have published patient-reported quality of life (QOL), but the size and heterogeneity of this literature can make patient education difficult. This meta-analysis aimed to describe change in QOL and symptomatology in patients receiving ICIs for cancer. METHODS: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, databases were searched through November 2019 for articles or abstracts of prospective, original studies reporting longitudinal QOL in adult cancer patients treated with ICIs. The prespecified primary outcomes were change in global QOL among patients treated with ICIs and difference in change since baseline in global QOL between patients treated with ICI vs non-ICI active treatment. Secondary outcomes included physical functioning and symptomatology. All statistical tests were 2-sided. RESULTS: Of 20 323 publications, 26 met inclusion criteria. Global QOL did not change over time in patients treated with ICIs (k = 26, n = 6974; P = .19). Larger improvements in global QOL was observed in patients receiving ICI vs non-ICI regimens (k = 16, ICI: n = 3588; non-ICI: n = 2948; P < .001). Physical functioning did not change in patients treated with ICIs (k = 14, n = 3169; P = .47); there were no differences in mean change between ICI vs non-ICI regimens (k = 11, n = 4630; P = .94). Regarding symptoms, appetite loss, insomnia, and pain severity decreased, but dyspnea severity increased in patients treated with ICIs (k = 14, n = 3243-3499; P < .001). Insomnia severity was higher in patients treated with ICIs than non-ICI regimens (k = 11, n = 4791; P < .001). CONCLUSIONS: This study is among the first to quantitatively summarize QOL in patients treated with ICIs. Findings suggest ICI recipients report no change in global QOL and higher QOL than patients treated with non-ICI regimens.
Authors: Fabio Conforti; Laura Pala; Vincenzo Bagnardi; Giuseppe Viale; Tommaso De Pas; Eleonora Pagan; Elisabetta Pennacchioli; Emilia Cocorocchio; Pier Francesco Ferrucci; Filippo De Marinis; Richard D Gelber; Aron Goldhirsch Journal: J Natl Cancer Inst Date: 2019-08-01 Impact factor: 13.506
Authors: Melanie Calvert; Jane Blazeby; Douglas G Altman; Dennis A Revicki; David Moher; Michael D Brundage Journal: JAMA Date: 2013-02-27 Impact factor: 56.272
Authors: Paolo A Ascierto; Georgina V Long; Caroline Robert; Benjamin Brady; Caroline Dutriaux; Anna Maria Di Giacomo; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Lars Ny; Ana Arance; Inge Marie Svane; Dirk Schadendorf; Helen Gogas; Abdel Saci; Joel Jiang; Jasmine Rizzo; Victoria Atkinson Journal: JAMA Oncol Date: 2019-02-01 Impact factor: 31.777
Authors: Jeffrey Weber; Mario Mandala; Michele Del Vecchio; Helen J Gogas; Ana M Arance; C Lance Cowey; Stéphane Dalle; Michael Schenker; Vanna Chiarion-Sileni; Ivan Marquez-Rodas; Jean-Jacques Grob; Marcus O Butler; Mark R Middleton; Michele Maio; Victoria Atkinson; Paola Queirolo; Rene Gonzalez; Ragini R Kudchadkar; Michael Smylie; Nicolas Meyer; Laurent Mortier; Michael B Atkins; Georgina V Long; Shailender Bhatia; Celeste Lebbé; Piotr Rutkowski; Kenji Yokota; Naoya Yamazaki; Tae M Kim; Veerle de Pril; Javier Sabater; Anila Qureshi; James Larkin; Paolo A Ascierto Journal: N Engl J Med Date: 2017-09-10 Impact factor: 91.245
Authors: Teresa M Petrella; Caroline Robert; Erika Richtig; Wilson H Miller; Giuseppe V Masucci; Euan Walpole; Celeste Lebbe; Neil Steven; Mark R Middleton; Darcy Hille; Wei Zhou; Nageatte Ibrahim; Jonathan Cebon Journal: Eur J Cancer Date: 2017-10-04 Impact factor: 9.162
Authors: Brian D Gonzalez; Sarah L Eisel; Kristina E Bowles; Aasha I Hoogland; Brian W James; Brent J Small; Susan Sharpe; Kelly A Hyland; Hailey W Bulls; Shannon M Christy; Jori Mansfield; Ashley M Nelson; Raviteja Alla; Kelly Maharaj; Brittany Kennedy; Elizabeth Lafranchise; Noelle L Williams; Sarah Jennewein; Laura B Oswald; Michael A Postow; Adam P Dicker; Heather S L Jim Journal: J Natl Cancer Inst Date: 2022-06-13 Impact factor: 11.816